Broadly protective vaccines against known and pre-emergent coronaviruses are urgently
needed. Critical to their development is a deeper understanding of cross-neutralizing …

Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs)
are urgently needed. To gain a deeper understanding of cross-neutralizing antibody …

The recent emergence of SARS-CoV-2 variants of concern (VOC) and the recurrent
spillovers of coronaviruses in the human population highlight the need for broadly …

Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …

The rapid emergence of SARS-CoV-2 variants that evade immunity to vaccination has
placed a global health imperative on the development of therapeutic countermeasures that …

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly
protective vaccines against coronaviruses that cause severe disease, for anticipating novel …

Antibodies play a pivotal role in protecting from SARS-CoV-2 infection, but their efficacy is
challenged by the continuous emergence of viral variants. In this study, we describe two …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly
protective vaccines against novel pandemic coronaviruses and to more effectively respond …

Developing broad coronavirus vaccines requires identifying and understanding the
molecular basis of broadly neutralizing antibody (bnAb) spike sites. In our previous work, we …